Drug Co. Misrepresented Products' FDA Status, SEC Says
The U.S. Securities and Exchange Commission hit BioChemics Inc. with a lawsuit Friday in Massachusetts federal court, accusing the biopharmaceutical company of selling investors $9 million worth of stock by falsely...To view the full article, register now.
Already a subscriber? Click here to view full article